The global fluorescent immunoassay market is witnessing significant growth due to increasing prevalence of chronic diseases such as atherosclerosis, hypertension, heart failure, diabetes, chronic kidney disease (CKD), and peripheral arterial disease (PAD). This market is driven by advancements in treatment modalities, encompassing medications, surgical interventions, and lifestyle modifications, as well as the development of various drug classes including vasodilators, antioxidants, nitric oxide donors, and endothelin receptor antagonists. In addition, the demand for fluorescent immunoassays in diverse end-user settings such as hospitals, ambulatory surgical centers, and specialty clinics is on the rise, fueled by the growing emphasis on accurate diagnostics and early disease detection, thereby enhancing patient outcomes and healthcare efficiency.
